Stoke Therapeutics/$STOK
Stoke Therapeutics falls after reporting Q3 revenue of $10.6 M, beating estimates, but EPS loss of $0.65 missed forecasts and announcing sale of 1.8 M shares via ATM offering, raising dilution concerns.
18 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Employees
128
Headquarters
Website
STOK Metrics
BasicAdvanced
$1.3B
33.33
$0.68
-
-
Price and volume
Market cap
$1.3B
52-week high
$38.69
52-week low
$5.35
Average daily volume
1.4M
Financial strength
Current ratio
6.529
Quick ratio
6.211
Profitability
EBITDA (TTM)
29.087
Gross margin (TTM)
100.00%
Net profit margin (TTM)
19.73%
Operating margin (TTM)
13.23%
Revenue per employee (TTM)
$1,610,000
Management effectiveness
Return on assets (TTM)
5.20%
Return on equity (TTM)
15.02%
Valuation
Price to earnings (TTM)
33.328
Price to revenue (TTM)
6.434
Price to book
4.08
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
25.264
Free cash flow yield (TTM)
3.96%
Free cash flow per share (TTM)
0.903
Growth
Revenue change (TTM)
1,128.17%
Earnings per share change (TTM)
-133.10%
3-year revenue growth (CAGR)
182.33%
3-year earnings per share growth (CAGR)
-35.99%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Bulls say / Bears say
The Biogen collaboration provided a $165 million upfront payment and cost-sharing for late-stage development, validating Stoke’s TANGO platform and funding its operations through mid-2028 without additional financing (Panabee).
Stoke ended Q2 2025 with $355 million in cash, cash equivalents, and marketable securities, granting a cash runway into mid-2028 and underpins its Phase 3 and launch readiness activities (Panabee).
Needham raised its price target to $35 on Oct 10, 2025, citing positive open-label extension data showing sustained improvements in cognition and behavior through three years in Dravet syndrome patients treated with zorevunersen (Investing.com).
The discontinuation of two Acadia-licensed TANGO programs reduces potential milestone and royalty payments, concentrating pipeline risk on zorevunersen’s success in the EMPEROR Phase 3 trial (Panabee).
Research and development expenses climbed 35% year-over-year to $58.5 million in H1 2025, reflecting a high cash burn that will accelerate as Stoke advances zorevunersen through pivotal Phase 3 studies (Panabee).
Despite strong technical momentum, Stoke’s EPS Rating is only 53 and its sales growth decelerated dramatically from 3,658% to 186% in Q2 2025, highlighting lagging earnings fundamentals ahead of commercialization (Investors.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Business Wire7 days ago
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
Business Wire2 weeks ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $1.3B as of November 06, 2025.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 33.33 as of November 06, 2025.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) does not currently have a Beta indicator.